XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
   Pulmonary Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

New NICE Guidance

Hypertension Channel
subscribe to Hypertension newsletter

Latest Research : Cardiology : Hypertension

   DISCUSS   |   EMAIL   |   PRINT
Beta Blockers No More First Choice for Hypertension
Jun 29, 2006 - 1:18:00 AM, Reviewed by: Dr. Sanjukta Acharya

The decision not to recommend Beta-blockers for first line therapy is based on evidence that suggests that they perform less well than other drugs, particularly in the elderly, and the increasing evidence that the most frequently used Beta-blockers at usual doses carries an unacceptable risk of provoking type 2 diabetes.

 
The National Institute for Health and Clinical Excellence (NICE), UK and the National Collaborating Centre for Chronic Conditions, in conjunction with the British Hypertension Society (BHS) on Wednesday 28 June launched the keenly awaited updated clinical guideline on the management of hypertension. The guideline updates the recommendations for the pharmacological management of hypertension contained in the original NICE guideline published in August 2004. Based on a thorough review of recently published data, the guideline sets the gold standard for the optimum pharmacological management of hypertension and in so doing seeks to decrease morbidity and mortality resulting from cardiovascular diseases such as stroke, chronic renal failure and coronary heart disease for which hypertension is a significant risk factor.

It is estimated that some 40 per cent of adults in England and Wales have hypertension and this proportion increases with age. In 2001, the NHS funded 90 million prescriptions for drugs that lower blood pressure, accounting for nearly 15 per cent of the total annual cost of all primary care drugs. Nonetheless, hypertension is often inadequately treated.

In formulating the recommendations, the Guideline Development Group (GDG) considered not only data from the new studies, but also adverse events data and a detailed health economic analysis comparing the cost-effectiveness of the main drug classes. The GDG also considered the cause, development, and effects of hypertension and the mechanism of action of the different classes of blood pressure lowering drugs allowing for age and ethnicity.

Beta Blockers No More First Choice for Hypertension
Courtesy: Blood Pressure Association (BPA)

The updated recommendations in the guideline include the following:
� In hypertensive patients aged 55 and over, or Black patients* of any age, first choice of initial therapy should be either a calcium channel blocker or a thiazide-type diuretic.
*Black patients are those of African or Caribbean descent, and not mixed race, Asian or Chinese patients.

� In hypertensive patients younger than 55, first choice initial therapy should be an ACE inhibitor (or an Angiotensin receptor blocker if an ACE inhibitor is not tolerated).

� If initial therapy was with a calcium channel blocker or thiazide-type diuretic and a second drug is required, add an ACE inhibitor (or an Angiotensin receptor blocker if an ACE inhibitor is not tolerated). If initial therapy was with an ACE inhibitor, add a calcium channel blocker or a thiazide-type diuretic.

� If treatment with three drugs is required, the combination of ACE inhibitor (or an Angiotensin receptor blocker if an ACE inhibitor is not tolerated), calcium channel blocker and thiazide-type diuretic should be used.


The decision not to recommend Beta-blockers for first line therapy is based on evidence that suggests that they perform less well than other drugs, particularly in the elderly, and the increasing evidence that the most frequently used Beta-blockers at usual doses carries an unacceptable risk of provoking type 2 diabetes. The guideline also makes recommendations beyond a 3-drug combination, where, although the evidence is less certain, the GDG took into account existing guidelines and constructed recommendations most compatible with current good practice.
 

- National Institute for Health and Clinical Excellence (NICE)
 

www.nice.org.uk/CG034guidance

 
Subscribe to Hypertension Newsletter
E-mail Address:

 

The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.

NICE produces guidance in three areas of health:
� public health � guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector
� health technologies � guidance on the use of new and existing medicines, treatments and procedures within the NHS
� clinical practice � guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.

The British Hypertension Society (BHS) provides a medical and scientific research forum to enable sharing of cutting edge research in order to understand the origin of high blood pressure and improve its treatment. The BHS has a track record of producing internationally renowned guidelines for the management of hypertension which are widely adopted in primary care in the UK and elsewhere. The BHS has also established an educational programme to support scientists, doctors and other healthcare workers involved in understanding the basis of high blood pressure and improving its treatment throughout the UK.

Four versions of the guidance will be available on the NICE website (www.nice.org.uk/CG034) from 28 June 2006:

� the full guideline, Clinical guideline 34: �Hypertension: management of hypertension in adults in primary care: partial update www.nice.org.uk/CG034guidance
� the NICE guideline, �Hypertension: management of hypertension in adults in primary care www.nice.org.uk/CG034NICEguideline
� a �Quick reference guide www.nice.org.uk/CG034quickrefguide (also available from the NHS Response Line � telephone 0845 155 455 and quote reference number N1050)
� information for patients and carers, �Understanding NICE guidance� www.nice.org.uk/CG034publicinfo (also available from the NHS Response Line � quote reference number N1051).


Related Hypertension News

Uric acid levels closely related to hypertension in Blacks
Is TROPHY misleading?
High blood pressure induces low fat metabolism in heart muscle
Beta Blockers No More First Choice for Hypertension
Job stress does not raise blood pressure
Blood Pressure Readings Lower when Patients Slow Down
Promising evidence of new drug therapies in Pulmonary arterial hypertension (PAH)
Fewer hours of sleep could lead to hypertension
Loneliness linked to high blood pressure in aging adults
Grape seed extract may be effective in reducing blood pressure


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us